Clinical trials: Breast Cancer, Metastatic
Breast Cancer
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12
The purpose of this study is to test the safety of an investigational Dendritic Cell/Tumor Fusion vaccine given with IL-12 for patients with breast cancer.
- Trial name
- NCT00622401
- Testing
- Dendritic Cell/Tumor Fusion Vaccine, Interleukin-12
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Beth Israel Deaconess Medical Center
Breast Cancer, Chemotherapeutic Agent Toxicity
L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
RATIONALE: L-carnitine L-tartrate may prevent peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well L-carnitine L-tartrate works in preventing peripheral neuropathy caused by…
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity
- Trial name
- NCT00754767
- Testing
- L-carnitine L-tartrate
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- HealthPartners Institute
Breast Advanced Malignancies
TDXD in Metastatic HER2-Positive Breast Cancer
A single-center observational study (retrospective + prospective) evaluating the real-world efficacy and toxicity profile of Trastuzumab Deruxtecan (T-DXd) in adult female patients with HER2-positive metastatic breast cancer…
- Trial name
- NCT07778407
- Testing
- Trastuzumab deruxtecan (T-DXd)
- Where
- Saudi Arabia
- Volunteers
- 25 people
- Sponsor
- Mansoura University
Advanced Breast Cancer, Metastatic Breast Cancer
"Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
The aim of this study is to assess benefits of treatment with intravenous Curcumin® (CUC-01) vs placebo, in combination with paclitaxel chemotherapy, and to estimate the risk of adverse events in patients with locally advanced…
- Trial name
- NCT03072992
- Testing
- Curcumin, Paclitaxel
- Where
- Armenia
- Volunteers
- 150 people
- Sponsor
- National Center of Oncology, Armenia
Breast Cancer
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
This is a multicenter, international, randomized, double-blinded, placebo-controlled, Phase II trial. Participants with advanced breast cancer (ABC) or Metastatic Breast Cancer (MBC) who have experienced recurrence or progression…
- Trial name
- NCT01437566
- Testing
- Fulvestrant, GDC-0941, GDC-0980
- Where
- 130 sites in United States, Argentina and 21 more
- Volunteers
- 318 people
- Sponsor
- Genentech, Inc.
Breast Cancer
Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women
RATIONALE: Studying mammograms for breast density changes over time may help doctors predict breast cancer risk. PURPOSE: This natural history study is looking at changes in breast density and gathering health information over…
- Trial name
- NCT00445445
- Testing
- physiologic testing, screening questionnaire administration, breast imaging study
- Where
- 8 sites in United States
- Volunteers
- 2,201 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer Invasive
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer
This study aims to explore the diagnostic performance of [18F]FES PET/CT for the evaluation of axillary lymph node metastasis in patients with ER-positive breast cancer having clinically suspected or confirmed axillary lymph node…
- Trial name
- NCT06695039
- Testing
- Fluoroestradiol (18F)
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Asan Medical Center
Breast Cancer
Carbon Suspension vs. Metallic Marker for Axillary Lymph Node Marking in Breast Cancer After Neoadjuvant Therapy
This single-center, randomized study aims to compare the intraoperative detection rates of axillary lymph nodes marked with carbon suspension versus metallic markers in breast cancer patients (T1-3N1M0) before neoadjuvant…
- Trial name
- COMET (NCT07106112)
- Testing
- Ultrasound-guided carbon suspension (Black Eye) injection, Ultrasound-guided metallic marker (TWIRL ULTRACOR) placement
- Where
- Russia
- Volunteers
- 110 people
- Sponsor
- Saint Petersburg State University, Russia
Breast Cancer
Self-Care for Lymphedema in Patients With Breast Cancer
RATIONALE: Identifying why patients don't do self care for lymphedema may help doctors plan better at-home self-care treatment. PURPOSE: This research study is looking at self-care practices for lymphedema in patients with breast…
- Trial name
- NCT00670644
- Testing
- questionnaire administration, survey administration, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Vanderbilt University
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Breast Cancer
Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
Study Objective: To evaluate the progression-free survival of HER-2 negative locally advanced or metastatic breast cancer subjects treated with eribulin in combination with erlotinib Trial Drug: Erlotinib Targets: Erlotinib is a…
- Trial name
- NCT06678230
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Hospital of Jilin University
TNBC - Triple-Negative Breast Cancer
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.
- Trial name
- NCT06387628
- Testing
- LM-108, Toripalimab, Eribulin
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fudan University
Breast Cancer
S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00041067
- Testing
- filgrastim, trastuzumab, docetaxel
- Where
- 145 sites in United States
- Volunteers
- 76 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Breast Cancer
A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
Comparing Docetaxel Plus Fulvestrant With Docetaxel in Patients With Metastatic Breast Cancer
- Trial name
- NCT02137083
- Testing
- Docetaxel, Fulvestrant
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy
Metastatic Breast cancer (MBC) patients from ten Italian Divisions of Medical Oncology, with histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v.
- Trial name
- BEVAPROS (NCT02329639)
- Testing
- genetic interaction analysis
- Where
- 2 sites in Italy
- Volunteers
- 307 people
- Sponsor
- University of Pisa
Stage IV Breast Cancer AJCC v6 and v7
Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer
This pilot clinical trial studies how well a ketogenic diet and chemotherapy work in affecting the return of cancer in patients with stage IV breast cancer.
- Trial name
- KETO-CARE (NCT03535701)
- Testing
- Dietary Intervention, Laboratory Biomarker Analysis, Paclitaxel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Doxorubicin in Treating Women With Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different forms may kill more tumor cells.
- Trial name
- NCT00003165
- Testing
- doxorubicin-HPMA conjugate
- Where
- 6 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Glasgow
Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors
Study Purpose and Design:A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 in Combination with Pembrolizumab Injection in Patients with…
- Trial name
- NCT05145907
- Testing
- TJ107 +Pembrolizumab
- Where
- 20 sites in China
- Volunteers
- 133 people
- Sponsor
- TJ Biopharma Co., Ltd.
Breast Cancer
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
The purpose of this study is to learn why certain drugs stop working in patients.In lab studies, tumors become resistant in several ways. Specific molecules seem to change and this may be why therapy stops working.
- Trial name
- NCT00897702
- Testing
- Blood draw, immunoenzyme technique, biopsy
- Where
- 7 sites in United States
- Volunteers
- 269 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Metastatic Breast Cancer
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer
The purpose of this study is to find out what effects, administering infusions of AUY922 with hormonal therapy (letrozole) and oral targeted drug (lapatinib) will have on the patients with advanced breast cancer known as ER+ HER2…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, HER-2 Positive Breast Cancer, ER Positive Breast Cancer
- Trial name
- NCT01361945
- Testing
- AUY922
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.